BR112015014775A2 - formulação, comprimido de desintegração oral, e, método para o tratamento de um indivíduo - Google Patents

formulação, comprimido de desintegração oral, e, método para o tratamento de um indivíduo

Info

Publication number
BR112015014775A2
BR112015014775A2 BR112015014775A BR112015014775A BR112015014775A2 BR 112015014775 A2 BR112015014775 A2 BR 112015014775A2 BR 112015014775 A BR112015014775 A BR 112015014775A BR 112015014775 A BR112015014775 A BR 112015014775A BR 112015014775 A2 BR112015014775 A2 BR 112015014775A2
Authority
BR
Brazil
Prior art keywords
formulation
treating
individual
disintegrating tablet
oral disintegrating
Prior art date
Application number
BR112015014775A
Other languages
English (en)
Inventor
A Pizzo Christopher
Djordjevic Jelena
Mohan Bommana Murali
H Shah Navnit
Phuapradit Wantanee
Original Assignee
Kashiv Pharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kashiv Pharma Llc filed Critical Kashiv Pharma Llc
Publication of BR112015014775A2 publication Critical patent/BR112015014775A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1 / 1 resumo “formulaã‡ãƒo, comprimido de desintegraã‡ãƒo oral, e, mã‰todo para o tratamento de um indivãduo” em alguns aspectos da presente invenã§ã£o ã© uma formulaã§ã£o compreendendo uma dispersã£o sã³lida ou uma mistura ã­ntima de uma droga pouco solãºvel em ã¡gua e um polã­mero iã´nico surpreendentemente exibindo rã¡pida desintegraã§ã£o de comprimido.
BR112015014775A 2012-12-20 2013-12-19 formulação, comprimido de desintegração oral, e, método para o tratamento de um indivíduo BR112015014775A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261739813P 2012-12-20 2012-12-20
US201361749040P 2013-01-04 2013-01-04
PCT/US2013/076578 WO2014100418A2 (en) 2012-12-20 2013-12-19 Orally disintegrating tablet formulation for enhanced bioavailability

Publications (1)

Publication Number Publication Date
BR112015014775A2 true BR112015014775A2 (pt) 2017-07-11

Family

ID=49950054

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015014775A BR112015014775A2 (pt) 2012-12-20 2013-12-19 formulação, comprimido de desintegração oral, e, método para o tratamento de um indivíduo

Country Status (8)

Country Link
US (2) US10195150B2 (pt)
EP (1) EP2934486A2 (pt)
CN (1) CN105007899A (pt)
AU (1) AU2013361307A1 (pt)
BR (1) BR112015014775A2 (pt)
CA (2) CA2895534C (pt)
RU (1) RU2015128794A (pt)
WO (1) WO2014100418A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016082705A1 (zh) * 2014-11-27 2016-06-02 华东理工大学 一种难溶性活性成分微粒、微粒制剂及其制备方法
HUP1500055A1 (hu) 2015-02-09 2016-08-29 Druggability Technologies Ip Holdco Ltd Abirateron acetát komplexei, eljárás elõállításukra, és az azokat tartalmazó gyógyászati készítmények
JP6507272B2 (ja) * 2015-07-27 2019-04-24 ユニケム ラボラトリーズ リミテッド トファシチニブ口腔内崩壊錠
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN106000220A (zh) * 2016-06-30 2016-10-12 东华大学 一种含化学试剂的有机溶剂崩解片的制备方法与应用
KR101849125B1 (ko) * 2016-12-12 2018-04-16 동화약품주식회사 프로톤 펌프 저해제를 포함하는 고체 분산체, 이의 제조방법 및 이를 포함하는 구강 붕해정
CN106880612A (zh) * 2017-02-14 2017-06-23 万全万特制药（厦门）有限公司 盐酸齐拉西酮口崩片及其制备方法
KR102148414B1 (ko) * 2017-05-15 2020-08-26 주식회사 서울제약 솔리페나신을 유효성분으로 하는 구강붕해필름
CN108926541A (zh) * 2017-05-26 2018-12-04 万全万特制药（厦门）有限公司 齐拉西酮口崩片及其制备方法
CN107669647B (zh) * 2017-10-30 2021-05-18 湖南中医药高等专科学校 一种右佐匹克隆口崩片及其制备方法
US10792262B1 (en) 2019-07-29 2020-10-06 Saol International Limited Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
US11654124B2 (en) 2019-07-29 2023-05-23 Amneal Pharmaceuticals Llc Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
AU2021212258A1 (en) 2020-01-31 2022-09-29 Nanocopoeia, Llc Amorphous nilotinib microparticles and uses thereof
US20220378788A1 (en) * 2020-04-30 2022-12-01 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib and in vitro characterization thereof
EP4142699A1 (en) * 2020-04-30 2023-03-08 Nanocopoeia LLC Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
RU2760129C1 (ru) * 2020-12-04 2021-11-22 Общество с ограниченной ответственностью "АМЕДАРТ" Твёрдая фармацевтическая композиция для изготовления перорального антиретровирусного терапевтического средства

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE53696B1 (en) 1981-12-02 1989-01-18 Wyeth John & Brother Ltd Solid shaped articles
HUT50044A (en) * 1988-04-12 1989-12-28 Bristol Myers Co Process for producing pharmaceutical composition comprising megestrol acetate as active ingredient
FR2671800B1 (fr) * 1991-01-17 1993-03-12 Rhone Poulenc Rorer Sa Derive de la 5h-pyrrolo[3,4-b]pyrazine optiquement actif, sa preparation et les compositions pharmaceutiques qui le contiennent.
HU225051B1 (en) 1994-03-02 2006-05-29 Organon Ireland Ltd Sublingual or buccal pharmaceutical compositions containing trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole
US6391338B1 (en) * 1995-09-07 2002-05-21 Biovail Technologies Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
ES2287971T3 (es) * 1997-08-11 2007-12-16 Pfizer Products Inc. Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
EP1120109A3 (en) * 2000-01-24 2002-07-10 Pfizer Products Inc. Rapidly disintegrating and fast dissolving solid dosage form
BR0307516A (pt) 2002-02-01 2004-12-07 Pfizer Prod Inc Formas de dosagem de liberação imediata contendo dispersões de uma droga sólida
RU2006102981A (ru) * 2003-08-04 2007-09-20 Пфайзер Продактс Инк. (Us) Лекарственные формы, обеспечивающие контролируемое высвобождение ингибиторов белка-переносчика эфиров холестерина и немедленное высвобождение ингибиторов hmg-соа-редуктазы
WO2008076780A2 (en) * 2006-12-14 2008-06-26 Isp Investments Inc. Amorphous valsartan and the production thereof

Also Published As

Publication number Publication date
US10195150B2 (en) 2019-02-05
CA2895534A1 (en) 2014-06-26
CA3053189A1 (en) 2014-06-26
CN105007899A (zh) 2015-10-28
CA2895534C (en) 2019-10-22
WO2014100418A2 (en) 2014-06-26
US20160120809A1 (en) 2016-05-05
WO2014100418A3 (en) 2014-08-28
US20190083403A1 (en) 2019-03-21
RU2015128794A (ru) 2017-01-25
AU2013361307A1 (en) 2015-07-09
EP2934486A2 (en) 2015-10-28

Similar Documents

Publication Publication Date Title
BR112015014775A2 (pt) formulação, comprimido de desintegração oral, e, método para o tratamento de um indivíduo
CY1124928T1 (el) Αναστολεις πυραζολυλο κινοξαλινο κινασης
BR112018076601A2 (pt) formulação farmacêutica oral, métodos para tratar um paciente, e, uso de uma formulação
CY1118661T1 (el) Φαρμακευτικη συνθεση, φαρμακευτικη δοσολογικη μορφη, διαδικασια για την παρασκευη τους, μεθοδοι για αντιμετωπιση και χρησεις αυτων
BR112017002777A2 (pt) formulação compreendendo partículas
CL2018000705A1 (es) Método de cristalización y biodisponibilidad
CL2016002308A1 (es) Nanopartículas que comprenden un ácido hidrofóbico, un copolímero de dibloque pla-peg o plga-peg, y 1 -4- 4-dimetilamino piperidin-1-il carbonilfenil-3-4-4,6-dimorfolin-4-il-1,3,5-triazin-2-ilfenilurea composición farmacética proceso de preparación y uso para tratar cáncer
BR112012028091A2 (pt) composições farmacêuticas compreendendo pioglitazona e linagliptina
MX356111B (es) Composiciones farmaceuticas disuasorias de abuso, de liberacion inmediata.
BR112015015870A2 (pt) composição farmacêutica
BR112015015858A8 (pt) composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica
BR112016001446A8 (pt) composições terapêuticas, produto de combinação, uso in vitro de flecainida e flecainida
BR112017003346B8 (pt) Derivados de pirazolopiridina, seus usos, e composição farmacêutica
EA201500742A1 (ru) Защищенные от нецелевого использования фармацевтические композиции
BR112013024824A2 (pt) ésteres isopentílicos para uso em composições cosméticas, dermatológicas ou farmacêuticas
PH12019500061A1 (en) Oral gastroretentive formulations and uses thereof
EP4233902A3 (en) Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
BR112015015864A8 (pt) composição farmacêutica, e, uso de uma composição farmacêutica
MX2017000041A (es) Formulaciones de liberacion inmediata disuasivas de abuso que comprenden polisacaridos no celulosicos.
BR112016024421A2 (pt) composição farmacêutica, cápsula e uso da composição farmacêutica
MX2017004772A (es) Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
BR112017009510A2 (pt) composições compreendendo ciclosporina
MY174729A (en) Pharmaceutical combination drug
BR112015012920A2 (pt) gel oral para dor de dente e sensibilidade
AR070392A1 (es) Composiciones de tabletas de ranitidina de desintegracion oral y sus metodos de eleboracion

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law
B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)